Regenerative Market Position Merakris as a growth partner in regenerative medicine for hard-to-heal wounds, leveraging MTX-001 and Dermacyte products to expand into hospital systems, VA supply chains, and wound care clinics.

Public Sector Momentum Capitalize on recent Federal Supply Schedule contract with the Department of Veterans Affairs and ongoing engagements at SAWC and IWH to target government and large healthcare networks for contract-driven deployments.

Clinical Progress Prioritize opportunities around MTX-001 IND status and upcoming regulatory milestones to engage payers and healthcare providers early with clinical data packages and potential reimbursement pathways.

Strategic Partnerships Leverage collaborations such as with iFyber to co-develop and co-market wound healing solutions, expanding reach into clinical research sites and accelerating evidence generation.

Scalable Biotech Highlight scalable stem cell–derived biotherapeutics and homeostasis-promoting therapies to attract partner CROs, contract manufacturers, and strategic investors seeking innovative, cost-effective regenerative treatments.